Method of predicting therapeutic effect of interferon treatment on hepatitis C

A prediction method and interferon technology, which can be used in measurement devices, biological testing, testing pharmaceutical preparations, etc., can solve problems such as large side effects, large differences in therapeutic effects, and high prices.

Inactive Publication Date: 2010-06-23
陈利民
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its shortcomings such as large differences in efficacy, high non-response rate, large side effects, and high price have plagued scientific researchers and clinical workers in various countries.
Therefore, this chemotherapy drug is only effective for breast cancer patients with HER-2 gene positive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of predicting therapeutic effect of interferon treatment on hepatitis C
  • Method of predicting therapeutic effect of interferon treatment on hepatitis C
  • Method of predicting therapeutic effect of interferon treatment on hepatitis C

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0032] The specific implementation is as follows:

[0033] 1. Acquisition of liver biopsy samples of hepatitis C patients: the current clinical practice requires routine liver biopsy samples to be taken before treatment to assess the degree of inflammation and fibrosis of the patient's liver; this test can be obtained by this routine method Liver biopsy samples without the need for a new liver biopsy.

[0034] 2. Liver biopsy samples were fixed with 10% formalin, embedded in paraffin, and cut into 4m thick slices. Routine staining with hematoxylin / eosin.

[0035] 3. ISG15 or MxA staining: After the above pathological sections were treated with Tris-EDTA (pH9.0) (MxA) or phosphate buffer (pH6.0) (ISG15), they were stained with mouse anti-human MxA monoclonal antibody (1:300 diluted) or rabbit anti-human ISG15 antiserum (diluted 1:300) was used for color development with the general color development kit MACH 4 Universal AP Polymer Kit (BiocareMedical, Concord, CA) after the p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an in vitro method of predicting the therapeutic effect of interferon treatment on a patient with hepatitis C, which belongs to the in vitro diagnostic reagent category of the biological medicine and is a substantive improvement based on a patent being applied for at present. The interferon treatment is effective only for 50 percent of patients with hepatitis C. The clinical operation is short of a method of predicting the therapeutic effect before the treatment of hepatitis C. According to the positioning and analysis of the expression of the ISG15 or MxA protein in the liver tissue through the immunohistochemical technique before the treatment of patients with hepatitis C, the distributions of ISG15 or MxA are different in the liver tissues of the patients for whom the interferon treatment is effective and the patients for whom the interferon treatment is not effective: the expression of the genes in the liver cells indicates that the interferon treatment is not effective for the patients; and the expression of the genes in the macrophage cells indicates that the interferon treatment is effective for the patients. The method is used to predict the therapeutic effects of the interferon treatment on 31 patients with hepatitis C, and the rate of accuracy reaches 100 percent. The invention can predict whether the patient with hepatitis C is sensitive to the interferon treatment before the interferon treatment, thereby optimizing the patient management.

Description

[0001] Technical field Biomedical in vitro diagnostic reagents Background technique [0002] my country is a big country with viral hepatitis, most of which are caused by hepatitis B virus (hepatitis B virus, HBV) and hepatitis C virus (hepatitis C virus, HCV) infection, the positive rate of hepatitis B surface antigen HBsAg in the general population is 9.09% , the prevalence of hepatitis C antibodies was 3.2% [1] . It is conservatively estimated that there are currently 20 million hepatitis B patients and 40 million hepatitis C virus-infected patients in China. However, more than 80% of the patients received non-standard treatment, which not only affected their health, but also wasted money. According to statistics, the direct medical expenses for the symptomatic treatment of hepatitis in my country exceed 50 billion yuan each year. The United States spends more than $1.98 billion annually on drugs for hepatitis C treatment alone. The persistence of HBV and HCV infection c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/15G01N33/68G01N33/576G01N33/577
Inventor 陈利民
Owner 陈利民
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap